Chilton资本管理公司在一家大型制药公司Novo Nordisk的股权增加了2.7%。 Chilton Capital Management increased its stake in Novo Nordisk, a major pharmaceutical company, by 2.7%.

奇尔顿资本管理有限公司在第一季度将丹麦新诺迪斯克A/S制药公司的股权增加了2.7%,现在拥有价值143万美元的20 547股股票。 Chilton Capital Management LLC increased its stake in Danish pharmaceutical firm Novo Nordisk A/S by 2.7% in the first quarter, now owning 20,547 shares worth $1.43 million. 诺沃诺迪斯克公司以每股0.92美元达到收入预期,并从事糖尿病、肥胖症和罕见疾病的工作。 Novo Nordisk met earnings expectations with $0.92 per share and operates in diabetes, obesity, and rare diseases. 该公司的市场上限为3 083.1亿美元,金融状况强劲,净利润为34.52%,股票回报率为80.94%。 The company has a market cap of $308.31 billion and a strong financial profile with a net margin of 34.52% and return on equity of 80.94%.